The Week

Akeso (9926.HK) added 12.57% this week to close at HK$101.2, outpacing the Hang Seng Index by about 12.24 percentage points; the benchmark rose only 0.33%. The week started weak and finished strong. On Monday 31 August the stock touched a low of HK$85.2 and ended at HK$85.65. Tuesday and Wednesday brought a narrow recovery between HK$87.8 and HK$90.8. Thursday 3 September saw a sharp pickup in volume, with 35.7m shares traded, pushing the price to a weekly high of HK$101.6 before a close near that level. Weekly amplitude was 18.24%, and average daily volume of 19.0m shares ran about 58% above the median.

Key Events

The week was dominated by ivonescimab clinical data. On 2 September, partner Summit Therapeutics reported that ivonescimab showed a statistically significant overall survival benefit versus pembrolizumab in first-line PD-L1-positive advanced non-small cell lung cancer in the HARMONi-2 study. Akeso followed with a voluntary announcement on the morning of 3 September, confirming the trial met its key secondary endpoint of overall survival at interim analysis with clinical benefit. The news kept building on 3 and 4 September, with broad coverage of the head-to-head survival result against Keytruda; Akeso shares rose roughly 9% to 11% intraday on 4 September. The same week, several brokers trimmed target prices, citing first-half 2026 results that came in below expectations.

Analyst Ratings

Based on the latest aggregated data, 24 firms cover Akeso: 18 rate it buy, 5 overweight and 1 hold, with no underweight or sell ratings. The consensus rating is strong buy. The consensus target price is HK$157.12, implying about 55.26% upside from the latest price of HK$101.2. Individual targets range widely, from HK$119.98 to HK$225.95. Akeso ranks second among 52 biotech names covered in its industry.

The Week Ahead

No company earnings or data events are scheduled for the coming week. On the macro calendar, Hong Kong’s unemployment rate is due on 17 September, after a prior reading of 3.7%. Closer at hand, the market is likely to keep digesting the HARMONi-2 overall survival readout, with attention on further ivonescimab indications and the pace of overseas development.

In Short

Akeso rallied sharply this week on clinical data, closing at HK$101.2. Broker coverage is broadly positive, with the consensus target above spot, although the target range is wide and several firms cut their targets this week after interim results disappointed. The price-to-book ratio sits at about 9.54x. On the latest trading day, large-lot money was a net buyer while retail flow leaned the other way. The key watchpoints are whether the clinical readout feeds through to clearer commercial and overseas execution, and whether earnings provide a fresh anchor.

This article is generated by LongbridgeAI from market data, for information only and not investment advice.